Neurogene completed the merger with Neoleukin Therapeutics in a $370m deal.

Neurogene, a clinical-stage company that focuses on developing genetic medicines for patients affected by rare neurological diseases, completed the merger with Neoleukin Therapeutics, a biopharmaceutical company, in a $370m deal. “This transformative transaction provides us with a strong cash position allowing us to demonstrate the best-in-class potential of our EXACT transgene regulation technology in treating Rett syndrome, a debilitating and complex neurological disease that cannot be treated with conventional gene therapy,” Rachel McMinn, Neurogene Founder and Chief Executive Officer.